Showing results (201-210 of 240) with videos related to
Sort By:
Pageof 24
Haematologica|October 13, 2004
Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantationAndrea Bacigalupo, Maria Pia Sormani, Teresa Lamparelli, et al.Blood|July 11, 2009
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)Ilaria Iacobucci, Clelia Tiziana Storlazzi, Daniela Cilloni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet studyDaniela Cilloni, Aline Renneville, Fabienne Hermitte, et al.British Journal of Haematology|September 3, 2013
Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host diseaseLynne M Ball, Maria E Bernardo, Helene Roelofs, et al.Clinical Lymphoma, Myeloma & Leukemia|March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase MyelofibrosisFrancesca Palandri, Massimo Breccia, Erika Morsia, et al.Blood|July 20, 2002
MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemiaAgostino Tafuri, Chiara Gregorj, Maria T Petrucci, et al.Annals of Hematology|March 20, 2016
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized studyAlois Gratwohl, Simona Iacobelli, Natalia Bootsman, et al.Blood Advances|June 11, 2026
A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with RuxolitinibFrancesca Palandri, Alessandra Dedola, Giovanni Caocci, et al.Cell Cycle (Georgetown, Tex.)|October 10, 2008
A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activityRaffaella Ponassi, Barbara Biasotti, Valeria Tomati, et al.Cancer|March 30, 2025
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life settingJacopo Nanni, Irene Azzali, Cristina Papayannidis, et al.Pageof 24